BRNS Barinthus Biotherapeutics (BRNS) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001828185
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
5
13F, latest reported quarter
BRNS filings, in plain words
Read the full summary
The latest 5% ownership filing is a 13D by International Generosity Foundation Trust, filed 2026-04-13, for 6.7% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Barinthus Biotherapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Barinthus Biotherapeutics plc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
5 funds bought in last quarter
below 95% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
no short interest reported
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch BRNS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-42.6%12M
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns BRNS: institutional holders (13F)
13F holdings, latest reported quarter
5,197,349 sh
$5.2M
1,420,473 sh
$937.5K
1,243,377 sh
$820.6K
642,204 sh
$423.9K
185,136 sh
$122.2K
Congress trades in BRNS
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
International Generosity Foundation Trust
Activist 13D · 2026-04-13
6.7%
BRNS planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
BRNS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Nasdaq Composite Index Fund
$7.6K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
1
Phase 2
0 active
1
Early Phase 1
1 active
3
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 5 funds added last quarter. Each figure is a federal filing, dated the day it went public.
BRNS financials
Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM BRNS
| FY Dec 2025 | n/a |
| FY Dec 2024 | $15.0M |
| FY Dec 2023 | $802.0K |
| FY Dec 2022 | $44.7M |
| FY Dec 2021 | $268.0K |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | $0 |
| Sep 2025 | $0 |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | $0 |
| Sep 2024 | $15.0M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM BRNS
| FY Dec 2025 | n/a |
| FY Dec 2024 | -408.0% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +11.9% |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -54.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$26.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM BRNS
| FY Dec 2025 | -$48.0M |
| FY Dec 2024 | -$29.8M |
| FY Dec 2023 | -$56.3M |
| FY Dec 2022 | -$20.6M |
| FY Dec 2021 | -$33.7M |
| Jun 2026 | -$8.1M |
| Mar 2026 | -$3.4M |
| Dec 2025 | -$4.2M |
| Sep 2025 | -$10.7M |
| Jun 2025 | -$18.1M |
| Mar 2025 | -$14.9M |
| Dec 2024 | $12.8M |
| Sep 2024 | -$18.3M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
current debt only, 2021-12-31 (54 months older than the period end); equity 2026-06-30
Debt to equity BRNS
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-166.19x
TTM operating cash flow over current debt only, 2021-12-31 (54 months older than the period end)
Cash flow to debt BRNS
| FY Dec 2025 | -301.75x |
| FY Dec 2024 | -182.01x |
| FY Dec 2023 | -320.28x |
| FY Dec 2022 | -90.76x |
| FY Dec 2021 | -204.92x |
| Jun 2026 | -166.19x |
| Mar 2026 | -229.20x |
| Dec 2025 | -301.75x |
| Sep 2025 | -192.77x |
| Jun 2025 | -239.77x |
| Mar 2025 | -201.38x |
| Dec 2024 | -182.01x |
| Sep 2024 | -387.60x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-52.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity BRNS
| FY Dec 2025 | -65.0% |
| FY Dec 2024 | -38.6% |
| FY Dec 2023 | -34.1% |
| FY Dec 2022 | +2.2% |
| FY Dec 2021 | -47.3% |
| Jun 2026 | -52.4% |
| Mar 2026 | -57.5% |
| Dec 2025 | -65.0% |
| Sep 2025 | -62.3% |
| Jun 2025 | -53.6% |
| Mar 2025 | -45.4% |
| Dec 2024 | -38.6% |
| Sep 2024 | -32.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-39.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets BRNS
| FY Dec 2025 | -51.4% |
| FY Dec 2024 | -32.6% |
| FY Dec 2023 | -30.3% |
| FY Dec 2022 | +1.9% |
| FY Dec 2021 | -30.7% |
| Jun 2026 | -39.5% |
| Mar 2026 | -44.7% |
| Dec 2025 | -51.4% |
| Sep 2025 | -50.9% |
| Jun 2025 | -43.9% |
| Mar 2025 | -38.2% |
| Dec 2024 | -32.6% |
| Sep 2024 | -27.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital BRNS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-46.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed BRNS
| FY Dec 2025 | -60.6% |
| FY Dec 2024 | -39.2% |
| FY Dec 2023 | -36.5% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -28.9% |
| Jun 2026 | -46.7% |
| Mar 2026 | -53.3% |
| Dec 2025 | -60.6% |
| Sep 2025 | -60.6% |
| Jun 2025 | -53.3% |
| Mar 2025 | -45.3% |
| Dec 2024 | -39.2% |
| Sep 2024 | -33.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing BRNS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 15.88x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
-$28.9M
market value at close 2026-09-18 on 2026-07-30 shares, plus current debt only, 2021-12-31 (54 months older than the period end), minus cash 2026-06-30
Enterprise value BRNS
| FY Dec 2025 | -$41.7M |
| FY Dec 2024 | -$61.9M |
| FY Dec 2023 | $374.9K |
| FY Dec 2022 | -$106.6M |
| FY Dec 2021 | $173.3M |
| Jun 2026 | -$32.2M |
| Mar 2026 | -$42.5M |
| Dec 2025 | -$41.7M |
| Sep 2025 | -$23.2M |
| Jun 2025 | -$48.6M |
| Mar 2025 | -$59.7M |
| Dec 2024 | -$61.9M |
| Sep 2024 | -$95.0M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-87.4%
TTM free cash flow over market value at close 2026-09-18
FCF yield BRNS
| FY Dec 2025 | -168.0% |
| FY Dec 2024 | -61.4% |
| FY Dec 2023 | -39.6% |
| FY Dec 2022 | -23.5% |
| FY Dec 2021 | -8.7% |
| Jun 2026 | -98.0% |
| Mar 2026 | -156.9% |
| Dec 2025 | -168.0% |
| Sep 2025 | -60.8% |
| Jun 2025 | -102.8% |
| Mar 2025 | -83.1% |
| Dec 2024 | -61.4% |
| Sep 2024 | -132.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing BRNS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-09-18. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $0 | $15.0M | $802.0K | $44.7M |
| Operating income | -$70.6M | -$68.0M | -$83.9M | -$4.0M |
| Net income | -$66.4M | -$61.1M | -$73.3M | $5.3M |
| EPS (diluted) | -1.64 | -1.55 | -1.91 | 0.14 |
| Operating cash flow | -$48.0M | -$28.9M | -$50.9M | -$14.4M |
| Cash | $70.5M | $110.7M | $142.1M | $194.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
BRNS Stock Sonar score 5/7 axes
Find similar shapesCompareBRNS ranks highest on profitability (53rd percentile) and risk and compliance (52nd), and lowest on growth (1st), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
